

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

VISEN PHARMACEUTICALS

维昇药业

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 2561)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of annual general meeting (the “**Notice of Annual General Meeting**”) of VISEN Pharmaceuticals (the “**Company**”) dated April 30, 2025, which set out the time and venue of the annual general meeting of the Company (the “**Meeting**”) and contain the resolutions to be considered by the shareholders of the Company at the Meeting.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the Meeting will be held as originally scheduled at Room 2605, 1788 Square, 1788 West Nanjing Road, Jing’an District, Shanghai, China at 3:00 p.m.

In addition to the resolutions set out in the Notice of Annual General Meeting, the following ordinary resolution will also be considered:

ORDINARY RESOLUTIONS

To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

7 “**THAT:**

the commercial supply framework agreement dated June 12, 2025 entered into between VISEN HK and Ascendis Europe (the “**Commercial Supply Framework Agreement**”), transaction contemplated thereunder, and the proposed annual caps in relation thereto be and are hereby generally and unconditionally approved, confirmed and ratified and the directors of the Company (“**Director(s)**”) acting together or by committee, or any Director acting individually, be and is hereby authorized to do all such further acts and things and execute such further documents and take all such steps which in his/her opinion may be necessary, desirable, or expedient to implement and/or give effect to or otherwise in connection with the terms of the Commercial Supply Framework Agreement or the continuing connected transactions contemplated thereby and thereunder.”

8 “THAT:

the grant of 435,000 Award Shares (as defined in the circular of the Company dated June 12, 2025, the “**Circular**”) (the “**Grant**”) to Mr. LU An-Bang (盧安邦) (“**Mr. Lu**”) be and is hereby approved, confirmed, and ratified and any Directors acting together or by committee, or any Director acting individually, be and is hereby authorized to do all such further acts and things and execute such further documents and take all such steps which in his/her opinion may be necessary, desirable, or expedient to implement and/or give effect to or otherwise in connection with the Grant or the transactions contemplated thereby and thereunder.”

By Order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
*Executive Director and
Chief Executive Officer*

Hong Kong, June 12, 2025

Notes:

- 1 A revised form of proxy (the “**Revised Form of Proxy**”) is enclosed with this supplemental circular of the Company dated June 12, 2025. Please refer to the section headed “**Annual General Meeting**” on pages 20 to 22 of this supplemental circular for the arrangements about the completion and submission of the Revised Form of Proxy.
- 2 Please refer to the Notice of Annual General Meeting for details of the other resolutions to be considered at the Meeting, closure of the register of members of the Company and eligibility for attending the Meeting and other relevant matters.

This supplemental circular (in both English and Chinese versions) has been posted on the Company’s website at <https://www.visenpharma.com>.

Shareholders may request for printed copy of this supplemental circular free of charge or change their choice of means of receipt and language of the Company’s corporate communications by sending reasonable notice in writing to the Company’s branch registrar in Hong Kong, Computershare Investor Services Limited, 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or by sending an email to visenpharma.ecom@computershare.com.hk.

Shareholders who have chosen to receive the Company’s corporate communications in either English or Chinese version will receive both English and Chinese versions of this supplemental circular since both languages are bound together into one booklet.

As of the date of this notice, the board of directors of the Company comprises (i) Mr. LU An-Bang as executive director, (ii) Mr. Michael Wolff JENSEN, Mr. Jan Møller MIKKELSEN, Mr. FU Shan, Mr. Michael J. CHANG, and Mr. CAO Yibo as non-executive directors, and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, and Ms. NI Hong as independent non-executive directors.